COLUMBUS, OH, August 27, 2025 /24-7PressRelease/ -- Christopher Edlin, PhD, has been selected for inclusion in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Dr. Edlin has established a distinguished career in the pharmaceutical industry, currently serving as the vice president of research and development at Hikma Pharmaceuticals PLC in Columbus, Ohio, since 2024. In this capacity, he oversees all research and development activities for generic products in North America, excluding sterile injectables. Dr. Edlin's leadership is characterized by his expertise in drug development within the generic sector, where he manages a team of approximately 100 scientists and drives innovation across the organization.

Before joining Hikma Pharmaceuticals, Dr. Edlin held several key positions at Teva Pharmaceutical Industries Ltd. between 2018 and 2024. He rose from director to senior director of research development and then to director of research development before being named the site head for global respiratory research and development in Waterford, County Waterford, Ireland. Dr. Edlin was responsible for the development of oral respiratory products, with a focus on asthma and chronic obstructive pulmonary disease.

From 2014 to 2018, Dr. Edlin was the executive director of the Pharmaceutical Manufacturing Technology Centre in Limerick. In this role, he led a partially government-funded research organization that operated on a membership basis, enabling companies to collaborate on shared research challenges by placing projects within local universities. Previously, Dr. Edlin excelled as the head of enterprise research partnerships at The University of Leicester in Leicester, United Kingdom, starting in 2012. He facilitated collaborations between academia and industry to foster innovation and drive impactful research initiatives.

Dr. Edlin's earlier career included significant contributions from the outset. After first working for Sanofi (formerly Sanofi-Aventis) in London as a senior medicinal chemist from 1998 to 2000, he became a team leader at F. Hoffmann-La Roche Ltd in Welwyn Garden City, U.K., until 2002. He then served as a principal scientist and group leader at GSK plc in Stevenage, U.K., from 2002 to 2006. Throughout these roles, Dr. Edlin worked across various therapeutic areas including HIV, arthritis, asthma and chronic obstructive pulmonary disease.

Dr. Edlin continually progressed, becoming group leader at Medical Research Council Technology in London until 2008, when he was recruited by iThemba Pharmaceuticals in South Africa. From 2008 to 2009, he served as the director of chemistry. He then became the head of chemistry and site head before being named chief scientific officer until 2012. During his time at iThemba, Dr. Edlin played a pivotal role in building the organization from its inception, training scientists to become effective drug discoverers and expanding the company from three to approximately 40 employees. Notably, iThemba Pharmaceuticals became the only organization on the African continent engaged in medicinal chemistry and drug discovery under his leadership. Dr. Edlin regards his work in South Africa as his most notable achievement.

Dr. Edlin's education began with a Bachelor of Science in chemistry at Durham University in 1995, followed by a Doctor of Philosophy in synthetic organic chemistry on campus in 1998. In pursuit of further expertise in business management within the pharmaceutical sector, he obtained a Master of Business Administration from the University of Limerick in 2017.

Dr. Edlin is an active member of several professional organizations, reflecting his commitment to advancing pharmaceutical science. He has been a fellow of the Royal Society of Chemistry since 2011 and serves as a board member for the International Pharmaceutical Aerosol Consortium on Regulation & Science. Additionally, he contributed as a board director for Britest Ltd. from 2016 to 2018. Dr. Edlin's dedication extends beyond professional pursuits into civic engagement and charitable activities. He has participated in Pelotonia's charity bike ride in Columbus and volunteers with the Mid-Ohio Food Collective.

Throughout his career, Dr. Edlin has achieved significant milestones, including securing 20 patents related to pharmaceutical innovations. He is also recognized for his scholarly contributions, with two dozen publications featured in Nature Biotechnology Research and various peer-reviewed journals.

In recognition of his contributions to science and education, Dr. Edlin received the African Network for Drug Discovery and Diagnostic Innovation Centre of Excellence Award from the World Health Organization and the African Network for Drugs and Diagnostics Innovation in 2011. Eager for future accomplishments, he aims to establish Hikma Pharmaceuticals as an industry-leading research and development organization while continuing to support scientific advancement through mentorship and collaboration within the global pharmaceutical community.

About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.

# # #